Diagnosis, Clinical Characteristics, and Clinical Outcomes of Hospitalized Patients
| Characteristic . | Hospitalized Patients (n = 18) . |
|---|---|
| Medical setting of presentation | |
| Wards | 15 (83.3) |
| Intensive care unit | 3 (16.7) |
| No. of skin lesions | |
| 0–10 | 8 (44.4) |
| 11–100 | 9 (50) |
| >100 | 0 |
| Not reported | 1 (5.6) |
| Size of maximal lesion, mm, median (range) | 4 (2–38) |
| Percentage of body affected, %, median (range) | 10 (2–80) |
| Area of rash distribution per major anatomical area | |
| Skin | 18 (100) |
| Anogenital | 11 (61.1) |
| Oral mucosal | 2 (11.1) |
| Ocular | 3 (16.7) |
| Concurrent diagnosis of superimposed bacterial infection | 8 (44.4) |
| Epiglottitis | 0 |
| Penile cellulitis | 3 |
| Periorbital cellulitis | 1 |
| Peritonsillar abscess | 1 |
| Pharyngitis and proctitis | 0 |
| Pharyngitis | 0 |
| Proctitis | 1 |
| Superimposed cellulitis | 2 |
| Duration of hospital stay, d, median | 4 |
| Reported history of at least 1 smallpox vaccination | 1 (5.6) |
| HIV positive | 13 (72.2) |
| Immunocompromising conditions | 7 (38.9) |
| HIV/AIDS | 4 |
| IBD on immunosuppressants | 1 |
| Kidney transplant | 1 |
| HIV/AIDS and multicentric Castleman disease | 1 |
| Systemic lupus erythematosus | 0 |
| Drug formulation (oral vs IV), no/No. (%) | 15/18 (83.3) |
| Completed or documented clinical outcomes, no./No. (%) | 8/18 (44.4)a |
| Completion of 14 d of therapy, no./No. (%) | 8/8 (100) |
| Clinical outcome, no./No. (%) | |
| Recovered from mpox infection | 7/8b (87.5) |
| Lesions or pain first started to improve, treatment day, median | 4 (n = 4) |
| Lesions and pain fully resolved, treatment day, median | 14 (n = 1) |
| Characteristic . | Hospitalized Patients (n = 18) . |
|---|---|
| Medical setting of presentation | |
| Wards | 15 (83.3) |
| Intensive care unit | 3 (16.7) |
| No. of skin lesions | |
| 0–10 | 8 (44.4) |
| 11–100 | 9 (50) |
| >100 | 0 |
| Not reported | 1 (5.6) |
| Size of maximal lesion, mm, median (range) | 4 (2–38) |
| Percentage of body affected, %, median (range) | 10 (2–80) |
| Area of rash distribution per major anatomical area | |
| Skin | 18 (100) |
| Anogenital | 11 (61.1) |
| Oral mucosal | 2 (11.1) |
| Ocular | 3 (16.7) |
| Concurrent diagnosis of superimposed bacterial infection | 8 (44.4) |
| Epiglottitis | 0 |
| Penile cellulitis | 3 |
| Periorbital cellulitis | 1 |
| Peritonsillar abscess | 1 |
| Pharyngitis and proctitis | 0 |
| Pharyngitis | 0 |
| Proctitis | 1 |
| Superimposed cellulitis | 2 |
| Duration of hospital stay, d, median | 4 |
| Reported history of at least 1 smallpox vaccination | 1 (5.6) |
| HIV positive | 13 (72.2) |
| Immunocompromising conditions | 7 (38.9) |
| HIV/AIDS | 4 |
| IBD on immunosuppressants | 1 |
| Kidney transplant | 1 |
| HIV/AIDS and multicentric Castleman disease | 1 |
| Systemic lupus erythematosus | 0 |
| Drug formulation (oral vs IV), no/No. (%) | 15/18 (83.3) |
| Completed or documented clinical outcomes, no./No. (%) | 8/18 (44.4)a |
| Completion of 14 d of therapy, no./No. (%) | 8/8 (100) |
| Clinical outcome, no./No. (%) | |
| Recovered from mpox infection | 7/8b (87.5) |
| Lesions or pain first started to improve, treatment day, median | 4 (n = 4) |
| Lesions and pain fully resolved, treatment day, median | 14 (n = 1) |
Data are presented as No. (%) unless otherwise indicated. This subgroup was characterized by a higher degree of severe immunocompromise and superimposed infections but ultimately achieved similar rates of improvement and resolution. Full clinical resolution of mpox disease was assessed at posttreatment assessment. Although more than half of patients were lost to follow-up, all patients demonstrated clinical improvement in illness prior to discharge (though assessment was limited in those who left against medical advice).
Abbreviations: HIV, human immunodeficiency virus; IBD, inflammatory bowel disease.
aOne patient was confirmed to have never taken tecovirimat (left against medical advice); thus, respective outcomes are excluded.
bOne patient had refractory and persistent disease, and died outside the timeframe of this study.
Diagnosis, Clinical Characteristics, and Clinical Outcomes of Hospitalized Patients
| Characteristic . | Hospitalized Patients (n = 18) . |
|---|---|
| Medical setting of presentation | |
| Wards | 15 (83.3) |
| Intensive care unit | 3 (16.7) |
| No. of skin lesions | |
| 0–10 | 8 (44.4) |
| 11–100 | 9 (50) |
| >100 | 0 |
| Not reported | 1 (5.6) |
| Size of maximal lesion, mm, median (range) | 4 (2–38) |
| Percentage of body affected, %, median (range) | 10 (2–80) |
| Area of rash distribution per major anatomical area | |
| Skin | 18 (100) |
| Anogenital | 11 (61.1) |
| Oral mucosal | 2 (11.1) |
| Ocular | 3 (16.7) |
| Concurrent diagnosis of superimposed bacterial infection | 8 (44.4) |
| Epiglottitis | 0 |
| Penile cellulitis | 3 |
| Periorbital cellulitis | 1 |
| Peritonsillar abscess | 1 |
| Pharyngitis and proctitis | 0 |
| Pharyngitis | 0 |
| Proctitis | 1 |
| Superimposed cellulitis | 2 |
| Duration of hospital stay, d, median | 4 |
| Reported history of at least 1 smallpox vaccination | 1 (5.6) |
| HIV positive | 13 (72.2) |
| Immunocompromising conditions | 7 (38.9) |
| HIV/AIDS | 4 |
| IBD on immunosuppressants | 1 |
| Kidney transplant | 1 |
| HIV/AIDS and multicentric Castleman disease | 1 |
| Systemic lupus erythematosus | 0 |
| Drug formulation (oral vs IV), no/No. (%) | 15/18 (83.3) |
| Completed or documented clinical outcomes, no./No. (%) | 8/18 (44.4)a |
| Completion of 14 d of therapy, no./No. (%) | 8/8 (100) |
| Clinical outcome, no./No. (%) | |
| Recovered from mpox infection | 7/8b (87.5) |
| Lesions or pain first started to improve, treatment day, median | 4 (n = 4) |
| Lesions and pain fully resolved, treatment day, median | 14 (n = 1) |
| Characteristic . | Hospitalized Patients (n = 18) . |
|---|---|
| Medical setting of presentation | |
| Wards | 15 (83.3) |
| Intensive care unit | 3 (16.7) |
| No. of skin lesions | |
| 0–10 | 8 (44.4) |
| 11–100 | 9 (50) |
| >100 | 0 |
| Not reported | 1 (5.6) |
| Size of maximal lesion, mm, median (range) | 4 (2–38) |
| Percentage of body affected, %, median (range) | 10 (2–80) |
| Area of rash distribution per major anatomical area | |
| Skin | 18 (100) |
| Anogenital | 11 (61.1) |
| Oral mucosal | 2 (11.1) |
| Ocular | 3 (16.7) |
| Concurrent diagnosis of superimposed bacterial infection | 8 (44.4) |
| Epiglottitis | 0 |
| Penile cellulitis | 3 |
| Periorbital cellulitis | 1 |
| Peritonsillar abscess | 1 |
| Pharyngitis and proctitis | 0 |
| Pharyngitis | 0 |
| Proctitis | 1 |
| Superimposed cellulitis | 2 |
| Duration of hospital stay, d, median | 4 |
| Reported history of at least 1 smallpox vaccination | 1 (5.6) |
| HIV positive | 13 (72.2) |
| Immunocompromising conditions | 7 (38.9) |
| HIV/AIDS | 4 |
| IBD on immunosuppressants | 1 |
| Kidney transplant | 1 |
| HIV/AIDS and multicentric Castleman disease | 1 |
| Systemic lupus erythematosus | 0 |
| Drug formulation (oral vs IV), no/No. (%) | 15/18 (83.3) |
| Completed or documented clinical outcomes, no./No. (%) | 8/18 (44.4)a |
| Completion of 14 d of therapy, no./No. (%) | 8/8 (100) |
| Clinical outcome, no./No. (%) | |
| Recovered from mpox infection | 7/8b (87.5) |
| Lesions or pain first started to improve, treatment day, median | 4 (n = 4) |
| Lesions and pain fully resolved, treatment day, median | 14 (n = 1) |
Data are presented as No. (%) unless otherwise indicated. This subgroup was characterized by a higher degree of severe immunocompromise and superimposed infections but ultimately achieved similar rates of improvement and resolution. Full clinical resolution of mpox disease was assessed at posttreatment assessment. Although more than half of patients were lost to follow-up, all patients demonstrated clinical improvement in illness prior to discharge (though assessment was limited in those who left against medical advice).
Abbreviations: HIV, human immunodeficiency virus; IBD, inflammatory bowel disease.
aOne patient was confirmed to have never taken tecovirimat (left against medical advice); thus, respective outcomes are excluded.
bOne patient had refractory and persistent disease, and died outside the timeframe of this study.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
